Carregant...
Fragment-based screening of programmed death ligand 1 (PD-L1)
The PD-1 immune checkpoint pathway is a highly validated target for cancer immunotherapy. Despite the potential ad-vantages of small molecule inhibitors over antibodies, the discovery of small molecule checkpoint inhibitors has lagged behind. To discover small molecule inhibitors of the PD-1 pathway...
Guardat en:
| Publicat a: | Bioorg Med Chem Lett |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6474755/ https://ncbi.nlm.nih.gov/pubmed/30728114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2019.01.028 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|